Press "Enter" to skip to content

Bluebird bio, Bristol-Myers’ multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/y4l_eaqIoAA/bluebird-bio-bristol-myers-multiple-myeloma-therapy-shows-promise-in-early-study-idINKBN1YD2ID